Discontinued Compounds. The rights granted to MRE under Section ---------------------- 2.1 shall revert to DTI with respect to the following compounds (hereinafter, such compounds shall be referred to as "Discontinued Compounds"): Those Selected Compounds or Co-Promoted Products as to which MRE has given written notice to DTI of its decision to discontinue Research and Development or Product Development.
Appears in 2 contracts
Sources: Development and Commercialization Agreement (Aderis Pharmaceuticals Inc), Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)
Discontinued Compounds. The rights granted to MRE under Section ----------------------
2.1 shall revert to DTI with respect to the following compounds (hereinafter, such compounds shall be referred to as "Discontinued Compounds"): Those Selected Compounds or Co-Promoted Products as to which MRE has given written notice to DTI of its decision to discontinue Research and Development or Product Development.
Appears in 1 contract
Sources: Development and Commercialization Agreement (Aderis Pharmaceuticals Inc)